Difference between revisions of "ADB-FUBINACA"
From Wiki Weed
(Created page with "'''ADB-FUBINACA''' is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/1069...") |
|||
| Line 1: | Line 1: | ||
| − | '''ADB-FUBINACA''' is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982, with a Ki value of 0.36nM at CB1. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like [[SDB-001]] and[[ STS-135]]. ADB-FUBINACA appears to be the product of rational drug design, since it differs from [[AB-FUBINACA]] only by the replacement of the isopropyl group with a tert-butyl group. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved. Nothing is known of the pharmacological activity of ADB-FUBINACA in humans or other animals. | + | '''ADB-FUBINACA''' is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982, with a Ki value of 0.36nM at CB1. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like [[SDB-001]] and[[STS-135 (drug)|STS-135]]. ADB-FUBINACA appears to be the product of rational drug design, since it differs from [[AB-FUBINACA]] only by the replacement of the isopropyl group with a tert-butyl group. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved. Nothing is known of the pharmacological activity of ADB-FUBINACA in humans or other animals. |
==See also== | ==See also== | ||
Latest revision as of 03:33, 14 April 2015
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982, with a Ki value of 0.36nM at CB1. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 andSTS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved. Nothing is known of the pharmacological activity of ADB-FUBINACA in humans or other animals.
